Cardiovascular diseases and nitric oxide in humans

Minerva Cardioangiologica

Volumn 48, Issue 11, 2000, Pages 379-386

  Ferlito, S ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b NONE   (Italy)

Author keywords

Arteriosclerosis; Cholesterol blood; Heart failure, congestive; Hypertension; Nitric oxide

Indexed keywords

ACETYLCHOLINE; ANTILIPEMIC AGENT; ARGININE DERIVATIVE; CYTOKINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANGINA PECTORIS; APHERESIS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; DRUG INFUSION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; PULMONARY HYPERTENSION; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; NITRIC OXIDE;

EID: 0034515335     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, Kugyama K, Ogawa H et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Cardiol 1998;31:1506-10.
2. Berkenboom G, Crasset V, Giot C, Unger P, Vachiery JL, Ledere JL. Endothelial function of internal mammary artery in patients with coronary artery disease and in cardiac transplant recipients. Am Heart J 1998;135: 488-94.
3. Tousoulis D, Davies GJ, Tentolouris C, Crake T. Lefroy DC, Toutouzas P. Effects of inhibition of nitric oxide synthesis in patients with coronary artery disease and stable angina. Eur Heart J 1997;18:608-13.
4. Kugyama K, Ungushi M, Sugyama S, Motoyama T, Kawano H, Hirashima O et al. Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina. Am J Cardiol 1997;79:606-10.
5. Quyyumi AA, Dakak N, Diodati JD, Cilligan DM, Panza JA, Cannon RO. Effect of L-arginine on human coronary endothelium dependent and physiologic vasodilation. J Am Coll Cardiol 1997;30:1220-7.
6. Bellamy MF, Goodfellow J, Twueddei AC, Brownee M, Gorman ST, Ellis GR. Oral L-arginine improves exercise tolerance and flow related endothelial dysfunction in microvascular angina. Circulation 1996;94:1-425
7. Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequence of atherosclerosis extend into the coronary microcirculation, restoration of endothelium dependent responses by L-arginine. Circ Res 1992;70: 405-76.
8. Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996;94:130-4.
9. Tagawa H, Mohri M, Ichiki T, Egashira K. L-arginine attenuates tachicardia-induced myocardial ischemia in patients with extensive coronary artery disease. Circulation 1997;96:1-316.
10. Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, Botas J, Cooke JP et al. Effect of L-arginine on coronary endothelial function in cardiac transplant patients: relation to vessel wall morphology. Circulation 1994;1615-23.
11. Salas E, Amado JA, Sanchez de Vega MJ, Poveda JJ, Berrazueta JR. Impaired vascular smooth muscle nitric oxide dependent relaxation in human coronary arteries from "transplant heart vasculopathy". Arch Int Cardio M 1997;67:11-6.
12. Nonamy Y. The role of nitric oxide in cardiac surgery. Surg Today 1997;27:583-92.
13. Node K, Hitekaze M, Kosaka H, Komamura K, Minamino T, Inoue M et al. Increased release of NO during ischemia reduces a myocardial contractility and improves metabolic dysfunction. Circulation 1996;93:356-64.
14. Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P. Inhibition of nitric oxide synthesis during the cold pressor test in patients with coronary artery disease. Am J Cardiol 1997;79:1676-9.
15. Newby DE, Flint LL, Fox KA, Boon NA, Webb DJ. Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol 1998;31:1585-90.
16. Ferlito S, Gallina M. Nitrite plasma levels in acute and chronic coronary heart disease. Minerva Cardioangiol 1997;45:553-8.
17. Node K, Kitakaze M, Sato H, Koretsune Y, Karita M, Kosaka H et al. Increased release of nitric oxide in ischemic hearts after exercise in patients with effort angina. J Am Cardiol 1998;32:63-8.
18. Kugiyama K, Ohgushi M, Motoyama T, Sugiyama S, Ogawa H, Yoshimura M M et al. Nitric oxide mediated flow dependent dilation is impaired in coronary arteries in patients with coronary spastic angina. J Am Coll Cardiol 1997;30:920-6.
19. Muller T, Haussmann HJ, Schepers G. Evidence for peroxynitrite as an oxidative stress inducing compound of aqueous cigarette smoke fractions. Carcinogenesis 1997:8.
20. Boger RH, Bode Boger SM, Thiele W, Junker W, Alexander K, Frolich C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95: 2068-74.
21. Komori K, Matsumoto T, Ishida M, Kuma S, Yonemitsu Y, Eguchi D. Enhancement of nitric oxide production after arterial reconstruction in patients with arteriosclerosis obliterans. J Vasc Surg 1997;26:657-62.
22. Slawinski M, Grodzinska L, Kostka Trabka E, Bieron K, Goszez A, Gryglewski RJ. L-arginine substrate for NO synthesis its beneficial effects in therapy of patients with peripheral arterial disease: comparison with placebo preliminary results. Acta Physiol Hung 1996;84; 457-8.
23. Bode Boger SM, Boger RH, Thiele W, Creutzig A, Alexander K, Frolic JC. L-arginine infusion therapy restores vascular NO production and improves the symptoms of intermittent claudication in patients with peripheral artery disease. Circulation 1997;96: 1-419.
24. Bundeshagen H, Alexander K. Dose related effect of intravenous L-arginine on muscular blood flow of the cal in patients with peripheral vascular disease: a H2150 position emission tomography study. Clin Sci Colch 1997;93:159-65.
25. Ferlito S, Gallina M. Nitrite endothelin and E-selectin plasma levels after arginine infusion in normal and vasculopathic subjects. Minerva Cardioangiol 1998;46: 471-7.
26. Ferlito S, Gallina M, Catassi S, Bisicchia A, Mugno F, Campo S et al. Livelli plasmatici di nitriti in soggetti normolipemici e ipercolesterolemici con arteriopatia periferica ostrurttiva. XVIII Conv Inter Sic Cal SIPV, Catania, 1997.
27. Ferlito S, Gallina M, Catassi S, Bisicchia A, Di Salvo MM. Nitrite plasma levels in normolipemic and hypercholesterolemic arteriopathics after vasoactive and lipid-lowering treatment. Panminerva Med 1994;1:1-3.
28. Bode Boger SM, Boger RH, Alfke H, Heinzed D, Tskikas D, Creutzig A et al. L-arginine induces nitric oxide dependent vasodilation in patients with critical limb ischemia, a randomized controlled study. Circulation 1996;93:85-90.
29. Mammon M, Vallet B, Bauter C, Wernert N, McFadden EP, Lablanche J. Long term oral administration of L arginine reduces intimal tickening and enhances neondothelium dependent acetylcholine induced relaxation after arterial injury. Circulation 1994;90:1357-62.
30. Tarry WC, Mackoul RG. L-arginine improves endothelium dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscl Thromb 1994;14:938-43.
31. Bauters C, Meurice I, Van Belle E, Lablanche JM, Bertrand ME. Endothelial dysfunction in cardiovascular disease: therapeutic implications after coronary angioplasty. Arch Mal Cœur Vaiss 1997;6:35-8.
32. Ferlito S, Gallina M, Pitari GM, Bianchi A. Nitric oxide plasma levels in patients with chronic and acute cerebrovascular disorders. Panminerva Med 1998;40:51-4.
33. Suzuki Y, Osuka K, Noda A, Tanazawa T, Takayasu M, Shihuya M et al. Nitric oxide metabolities in the cisternal cerebral spinal fluid of patients with subarachnoid hemorrhage. Neurosurgery 1997;41:807-11.
34. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation. 1998;30:2494-8.
35. Wilcox JN, Subramaniam RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997;17:2479-88.
36. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, Keaney JF. L-2 Oxothiazolidine-4-carboxylic acid reverse endothelial dysfunction in patients with coronary artery disease. J Clin Invest 1998;101:1408-14.
37. Shimizu S, Nomoto N, Naito S, Yamamoto T, Nomose K. Stimulation of nitric oxide synthase during oxidative endothelial cell injury. Biochem Pharmacol 1998;55: 73-63.
38. Egashira K. Inou T, Yamada A, Hirooka Y, Maruoka Y, Takashita A. Impaired coronary blood flow responses to acetylcholine in patients with coronary risk factors and proximal atherosclerotical lesions. J Clin Invest 1993;91:29-37.
39. Adams MR, Robinson J, McCredie R, Seale JP, Sorensen KE, Deanfield JE et al. Smooth muscle dysfunction occurs independently of impaired endothelium dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol 1998;32:123-7.
40. Thorne S, Muller MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adult at risk from atherosclerosis different responses to L-arginine. J Am Coll Cardiol 1998;32:110-6.
41. Uwabo J, Soria M, Nakayama T, Kanmatsuse K. Association of variable number of tandem repeats in the endohtelial constitutive nitric oxide synthase gene with essential hypertension in Japanese. Am J Hypertens 1998;11:125-8.
42. Lacolley P, Gautier S, Poirier O, Pannier B, Cambien F, Benetos A. Nitric oxide synthase gene polymorphism, blood pressure and aortic stiffness in normotensive and hypertensive subjects. J Hypertens 1998;16:31-5.
43. Node K, Kitakaze M, Yoshikawa H, Kosaka H, Hori M. Reduced plasma concentrations of nitrogen oxide in individual with essential hypertension. Hypertension 1997;30:405-8.
44. Taddei S, Virdis A, Mattei P, Ghiandoni L, Sudano I, Salvetti A. Defective L-arginine nitric oxide pathway in offspring it essential hypertensive patients. Circulation 1996;94:1298-303.
45. Taddei S, Virdis A, Mattei D, Ghiandoni L, Gennari A, Sudano I et al. Aging and endothelial function in normotensive subjects and essential hypertensive patients. Circulation 1995;91:1981-7.
46. Cardillo C, Kilcoyne CM, Quyyumi AA, Canno RO 3rd, Panza A. Selective defect in nitric oxide synthesis may explain the impaired endothelium dependent vasodilation in patients with essential hypertensione. Circulation 1998;97:851-6.
47. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998;97:2222-9.
48. Linder L, Klowki W, Buhler FA, Lusched TF. Indirect evidence for the release of endothelium derived relaxing factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990;81:1762-7.
49. Calver A, Collir J Moncada S, Vallance P. Effect of local intrarterial N monomethil L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypert 1992;20:1025-31.
50. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9.
51. Goonasekera CD, Shah V, Rees DD, Dillon MJ. Nitric oxide activity in childhood hypertension. Arch Dis Child 1997;77:11-6.
52. Schiffrin EL. Resistance arteries as endpoints in hypertension. Blood Press Suppl 1997;2:224-30.
53. Noll G, Tschudi M, Nava E, Luscher TF. Endothelium and high blood pressure. Int J Microcirc Clin Exp 1997;17:273-9.
54. Panza JA, Xasino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium derived oxide in the abnormal endothelium dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-74.
55. James MA, Watt PA, Potter JE, Thruston H, Swales D. Endothelial function in subcutaneous resistance arteries from elderly hypertensive and nonnotensive subjects. Clin Sci Colch 1997;92:139-45.
56. Cockcroft JR, Chowienczyk PJ, Benjamin B, Ritter FM. Preserved endothelium dependent vasodilation in patients with essential hypertension. Engl J Med 1994;330:1036-40.
57. Chowienczyk PJ, Watts GF, Cockroft JR, Ritter JM. Impaired endothelium dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet 1992;340:1430-2.
58. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990;86:228-34.
59. Cilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Canno RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994;90:35-41.
60. Ferlito S, Gallina M. Nitrite plasma levels in hypercholesterolemic coronarophatics and diabetic patients. Perfusion 1998;11:335-7.
61. Egashira K, Hirooka Y, Kay H, Sugimachi M, Suzuki S, Inou T et al. Reduction in serum cholesterol with pravastatin improves endothelium dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-24.
62. Boccuzzi SJ, Cederholm JC, Alexander RW. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-7.
63. O'Driscoll G, Green D, Taylor R. Simvastatin, an HMG Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-32.
64. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol lowering therapy on coronary endothelium dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-500.
65. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolemic patients off and on lipid lowering medication. Lancet 1995;346:467-71.
66. Druy J, Cohen JD, Veerendrababu B, Flaker G, Donohue TJ, Labovitz AJ. Brachial artery endothelium dependent vasodilation in patients controlled in the cholesterol and recurrent events (CARE) study. Circulation 1996;94:1-402.
67. Creager MA, Gallagher SJ, Girerd XKJ, Coleman SM, Dzau VJ, Cooke JP et al. L-arginine improves endothelium dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53.
68. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microvasculature of hypercholesterolemic patients by L-arginine. Lancet 1991;338:1546-50.
69. Tamal O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T, Single LDL apheresis improves in endothelium dependent vasodilation in hypercholesterolemic humans. Circulation 1997;95:76-82.
70. Garcia CE, Kilcoyne CM, Cardillo C, Canno RO, Quyymi AA, Panza JA. Evidence that endothelial dysfunction in patients with hypercholesterolemia is not due to increased extracellular nitric oxide break down by superoxide anions. Am J Cardiol 1995;76:1157-61.
71. Gautier TW, Scalia R, Murohara T, Guo JP, Leter AM. Nitric oxide protects against leukocyte endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:1652-9.
72. Sumino H, Sato K, Sakamaki T, Masuda H, Nakamura T, Kanda T et al. Decreased basal production of nitric oxide in patients with heart failure. Chest 1998;113: 317-22.
73. Mohri M, Egashira K, Tagawa T, Kuga T, Tagawa H, Harasaw Y et al. Basal release of nitric oxide is decreased in the coronary circulation in patients with heart failure. Hypertension 1997;30:50-6.
74. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998;97:363-8.
75. Minamino T, Kitaakaze M, Sato H, Asanuma H, Funaya H, Koretsune Y et al. Plasma levels of nitrite/nitrate and platelet c GMP levels are decreased in patients with atrial fibrillation. Arterioscler Thromb Vasc Biol 1997;17:3191-5.
76. Ikeda U, Shimada K. Nitric oxide and cardiac failure. Clin Cardiol 1997;20:837-41.
77. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998;62:2425-30.
78. Fukuchi M, Hussain SN, Giaid A. Heterogenous expression and activity of endothelial and inducible nitric oxide synthases in end stage human heart failure: their relation to lesion site and beta adrenergic receptor therapy. Circulation 1998;98:132-9.
79. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta adrenergic inotropic responsiveness. Circulation 1998;97: 161-6.
80. Arnal JF, Galinier M, Mazerolles M, Rami J, Besombes JP, Fauvel JM et al. Nasal nitric oxide concentration is decreased in heart failure patients receiving nitrates. Fundam Clin Pharmacol 1998;12:95-100.
81. Rectors TS, Nank AJ, Miller KA, Tschumperlin LK, Sih R, Pillai K. Randomized, double blind, placebo controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-41.
82. Kahn T, Kats S. Specific assessment of synthetic activity of the L-arginine nitric oxide metabolic pathway at rest and during exercise in patients with heart failure and normal subjects. Circulation 1996;94:1-495.
83. Hayward CS, Kalnins WV, Roger P, Feneley MP, MacDonald PS, Kelly RP. Effect of inahled nitric oxide on normal human left ventricular function. J Am Coll Cardiol 1997;30:49-56.
84. Wagner F, Dandel M, Gunther G, Loebe M, Schulze Neick I, Laucke U et al. Nitric oxide inhalation in the treatment of right ventricular dysfunction following left ventricular assist device implantation. Circulation 1997;(II)96:291-6.
85. Bocchi EA, Auler JO Jr, Guimaraes GV, Carmona MJ, Wajngarten M, Bellotti G et al. Nitric oxide inhalation reduces pulmonary tidal volume during exercise in severe chronic heart failure. Am Heart J 1997;134: 737-44.